First Trust Advisors’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

First Trust Advisors’s Portfolio DRNA Stock Details DRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-134,599	Closed	-$2.71M	–	2649
2021 Q3	$2.71M	Buy	134,599 +44,222	+49%	+$1.22M	﹤0.01%	1644
2021 Q2	$3.37M	Buy	90,377 +43,885	+94%	+$1.35M	﹤0.01%	1593
2021 Q1	$1.19M	Buy	46,492 +15,266	+49%	+$390K	﹤0.01%	1927
2020 Q4	$688K	Sell	31,226 -49,498	-61%	-$1.09M	﹤0.01%	2032
2020 Q3	$1.45M	Sell	80,724 -16,940	-17%	-$351K	﹤0.01%	1550
2020 Q2	$2.48M	Sell	97,664 -33,782	-26%	-$728K	﹤0.01%	1280
2020 Q1	$2.42M	Buy	131,446 +62,687	+91%	+$1.22M	0.01%	1184
2019 Q4	$1.51M	Buy	+68,759	New	+$1.38M	﹤0.01%	1692

Other funds holding DRNA

CAM

Close Asset Management London, United Kingdom $3.69B AUM 21.62% 1-Year Est. Return

First Trust Advisors's DRNA Position: Q4 2021 in Review

First Trust Advisors sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q4 2021, closing a stake of 134,599 shares — an estimated $2.71M sold.

First Trust Advisors first reported a position in DRNA in Q4 2019 and held it in 8 quarters. The position peaked at $3.37M in Q2 2021. 1 fund tracked by Wall St. Rank holds DRNA as of Q4 2021.

First Trust Advisors reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q4 2021 after selling out during the quarter.
First Trust Advisors sold 134,599 Dicerna Pharmaceuticals, Inc. shares in Q4 2021, an estimated $2.71M.
First Trust Advisors first reported a position in Dicerna Pharmaceuticals, Inc. in Q4 2019 and held it in 8 quarters.
First Trust Advisors's Dicerna Pharmaceuticals, Inc. position peaked at $3.37M in Q2 2021.
1 fund tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q4 2021.

Based on First Trust Advisors's 13F filing for Q4 2021, filed 8 Feb 2022.